No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Hong Kong Stock Announcement Gold Mining | CHINA OVERSEAS reported annual performance with a profit attributable to Shareholders of 15.636 billion yuan, a decrease of 38.95% year-on-year.
FOSUN PHARMA (02196) plans to invest 0.27 billion yuan to subscribe for UnitedHealth insurance's 0.105 billion newly issued shares; Keji Pharmaceuticals-B (02171): A summary of the research results for ShuRuiJia'O LunSai injection has been accepted for oral presentation at the 2025 ASCO Annual Meeting.
Kojie Pharmaceutical (02171.HK) cancer treatment drug for stomach cancer has been accepted for an oral presentation at the USA ASCO annual meeting.
Kejia Pharmaceutical-B (02171.HK) announced that the results summary of the confirmatory Phase II clinical trial of Shurekigoran injection conducted in China has been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) annual meeting. The summary and further information will be announced after May 22, Eastern Time this year. It is reported that Shurekigoran injection is used for the treatment of Claudin18.2 positive solid tumors, mainly treating gastric cancer/esophagogastric junction adenocarcinoma and pancreatic cancer.
Kangji Pharmaceutical-B (02171.HK): The summary of the research results for Shureki Aolunsei injection has been accepted for an oral presentation at the 2025 ASCO Annual Meeting.
On March 31, Gelonghui reported that Keji Pharmaceuticals-B (02171.HK) announced that the research results summary of Shurekio Lorsan Injection (Product Number: CT041, a CAR-T cell therapy candidate targeting Claudin18.2 protein) for advanced gastric/esophagogastric junction adenocarcinoma in China has been accepted for oral presentation at the 2025 American Society of Clinical Oncology (ASCO) annual meeting. The summary and further information will be available at 20 Eastern Time in the USA.
Kejia Pharmaceutical-B (02171.HK): CT041 is about to enter NDA for universal multi-line advancement.
Investment Highlights: Computed Tomography 053 has started to contribute to performance, Computed Tomography 041 is about to file for NDA, and the universal CAR-T pipeline is progressing. There is a bullish outlook on the company's leading advantages and price in the field of solid tumor CAR-T and universal CAR-T.
Hong Kong stock movement | Kira Pharmaceuticals-B (02171) rose nearly 7% in the afternoon, and Saikeze has begun to contribute revenue. The CT041 plan is set to submit an NDA.
Kojii Pharmaceutical-B (02171) surged nearly 7% in the afternoon, reaching a rise of 6.73% as of this report, priced at 13.32 HKD, with a transaction volume of 54.5483 million HKD.
Kezhi Pharmaceutical-B (02171.HK) received an increase in shareholding of 28.6315 million shares Listed in Hong Kong from Peking Shen Nong Investment Management Co., Ltd., valued at approximately 0.257 billion Hong Kong dollars.
On March 20, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on March 20, Peking Shennong Investment Management Co., Ltd. increased its shareholding in $Kojin Pharmaceutical-B (02171.HK)$ by a total of 28.6315 million H shares at an average on-market price of 8.98 HKD per share and an average off-market price of 13.2 HKD per share, worth approximately 0.257 billion HKD. After the shareholding increase, Peking Shennong Investment Management Co., Ltd. now holds 28.6315 million shares, with the shareholding ratio rising from 4.91% to 5.01%. Image source: Stock disclosure by the Stock Exchange. What is equity disclosure? According to
